ICER finds Biogen’s new exorbitantly priced Alzheimer’s drug doesn’t match even an optimistic view of potential clinical benefits

Even with a rosy outlook on how Biogen’s new Alzheimer’s drug will help those with the debilitating and fatal disease, the Institute for Clinical and Economic Review on Wednesday said the $56,000 annual price tag “is not in reasonable alignment with its clinical benefits.”